Odit Gutwein

1.0k total citations
17 papers, 415 citations indexed

About

Odit Gutwein is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Odit Gutwein has authored 17 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Genetics and 7 papers in Hematology. Recurrent topics in Odit Gutwein's work include Multiple Myeloma Research and Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Odit Gutwein is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Odit Gutwein collaborates with scholars based in Israel, Switzerland and Germany. Odit Gutwein's co-authors include Maya Koren‐Michowitz, Naomi Rahimi‐Levene, Abraham Kornberg, Yossi Cohen, Arie Apel, Arnon Nagler, Merav Leiba, Eithan Galun, Hanna Wald and Katia Beider and has published in prestigious journals such as Blood, Journal of Thrombosis and Haemostasis and Oncotarget.

In The Last Decade

Odit Gutwein

15 papers receiving 412 citations

Peers

Odit Gutwein
Kuang‐Yueh Chiang United States
Sai Ravi Pingali United States
Fábio R. Kerbauy Brazil
Christine‐Ivy Liacos Greece
Gergely Kriván Hungary
Ivan Moiseev Russia
Masahiro Yasui Japan
László Gopcsa Hungary
Masatoshi Sakurai Japan
Jesse Keller United States
Kuang‐Yueh Chiang United States
Odit Gutwein
Citations per year, relative to Odit Gutwein Odit Gutwein (= 1×) peers Kuang‐Yueh Chiang

Countries citing papers authored by Odit Gutwein

Since Specialization
Citations

This map shows the geographic impact of Odit Gutwein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Odit Gutwein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Odit Gutwein more than expected).

Fields of papers citing papers by Odit Gutwein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Odit Gutwein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Odit Gutwein. The network helps show where Odit Gutwein may publish in the future.

Co-authorship network of co-authors of Odit Gutwein

This figure shows the co-authorship network connecting the top 25 collaborators of Odit Gutwein. A scholar is included among the top collaborators of Odit Gutwein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Odit Gutwein. Odit Gutwein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Wertheimer, Tobias, Odit Gutwein, Ester Cannizzaro, et al.. (2023). Deciphering the Dynamics of the B-NHL Single-Cell Landscape during BTK Inhibition. Blood. 142(Supplement 1). 3007–3007. 1 indexed citations
3.
Beyar‐Katz, Ofrat, Chava Perry, Yael Bar‐On, et al.. (2022). Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience. Annals of Hematology. 101(8). 1769–1776. 19 indexed citations
4.
Gutwein, Odit, et al.. (2021). BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. American Journal of Hematology. 96(10). 1195–1203. 106 indexed citations
5.
Kirgner, Ilya, Odit Gutwein, Katrin Herzog‐Tzarfati, et al.. (2021). Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. Journal of Thrombosis and Haemostasis. 19(9). 2314–2317. 36 indexed citations
6.
Bentur, Ohad S., Eldad J. Dann, Esther Paran, et al.. (2019). Interim PET-CT–guided therapy in elderly patients with Hodgkin lymphoma—a retrospective national multi-center study. Annals of Hematology. 98(7). 1665–1674. 5 indexed citations
7.
Gutwein, Odit, et al.. (2019). Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study. Clinical Lymphoma Myeloma & Leukemia. 19(12). 812–814. 5 indexed citations
8.
Ribakovsky, Elena, Abraham Avigdor, Vladimir Vainstein, et al.. (2019). Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data. Blood. 134(Supplement_1). 5321–5321. 4 indexed citations
9.
Gutwein, Odit, Naomi Rahimi‐Levene, Katrin Herzog‐Tzarfati, et al.. (2017). Low Protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels. Leukemia Research. 62. 104–107.
10.
Bentur, Ohad S., Ronit Gurion, Anat Gafter‐Gvili, et al.. (2017). Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?. Leukemia & lymphoma. 59(5). 1163–1171. 3 indexed citations
11.
Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2015). Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. Leukemia Research. 39(11). 1154–1158. 7 indexed citations
12.
Beider, Katia, Merav Leiba, Odit Gutwein, et al.. (2014). Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 5(22). 11283–11296. 134 indexed citations
13.
Cohen, Yossi, et al.. (2014). Bone Marrow Expression of CCL3 Is Not Correlated with the Extent of Lytic Bone Lesions. Acta Haematologica. 132(2). 129–133. 1 indexed citations
14.
Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2014). Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting. Blood. 124(21). 1830–1830. 1 indexed citations
15.
Cohen, Yossi, et al.. (2013). GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 18(6). 348–351. 43 indexed citations
16.
17.
Marom, Daphna, Itzhak Levy, Odit Gutwein, Einat Birk, & Shai Ashkenazi. (2011). Healthcare-associated Versus Community-associated Infective Endocarditis in Children. The Pediatric Infectious Disease Journal. 30(7). 585–588. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kuang‐Yueh Chiang Breakdown of academic impact, for papers by Sai Ravi Pingali Breakdown of academic impact, for papers by Fábio R. Kerbauy Breakdown of academic impact, for papers by Christine‐Ivy Liacos Breakdown of academic impact, for papers by Gergely Kriván Breakdown of academic impact, for papers by Ivan Moiseev Breakdown of academic impact, for papers by Masahiro Yasui Breakdown of academic impact, for papers by László Gopcsa Breakdown of academic impact, for papers by Masatoshi Sakurai Breakdown of academic impact, for papers by Jesse Keller
Rankless by CCL
2026